Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524966 | 0.86 | SLC1A3 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14524935 | 0.84 | ALOX5 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9926556 | 0.83 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL6123720 | 0.82 | CYP3A4 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15093979 | 0.81 | CYP3A4 (0.48) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL12226956 | 0.79 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL171203 | 0.79 | CYP3A4 (0.43) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL998743 | 0.79 | CYP3A4 (0.43) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL27628619 | 0.79 | CYP3A4 (0.43) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL1154758 | 0.78 | IDO1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238611-B2 | Process for separating aryl carboxylic acids | RELIANCE INDUSTRIES LIMITED (IN) | 2016-01-19 | — | — | US | claimed |
| US-20150065748-A1 | PROCESS FOR SEPARATING ARYL CARBOXYLIC ACIDS | RELIANCE INDUSTRIES LIMITED (IN) | 2015-03-05 | — | — | US | claimed |
| EP-2831027-A1 | A PROCESS FOR SEPARATING ARYL CARBOXYLIC ACIDS | Reliance Industries Limited (IN) | 2015-02-04 | — | — | EP | claimed |
| WO-2013164852-A1 | A PROCESS FOR SEPARATING ARYL CARBOXYLIC ACIDS | RELIANCE INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| CN-119569635-A | Biaryl ring inhibitors targeting c-Myc proteins | 上海深势唯思科技有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| CN-113979835-B | Synthesis method of pazopanib trimer impurity intermediate | 重庆医科大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-113979835-B | Synthesis method of pazopanib trimer impurity intermediate | 重庆医科大学 | 2023-09-26 | — | — | CN | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| CN-1882347-A | AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004055013-A1 | [1,7]NAPHTHYRIDINES AS PDE4 INHIBITORS | NOVARTIS AG (CH) | 2004-07-01 | — | — | WO | disclosed |
| US-4139530-A | CATIONIC DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | PSEN1 125/4885PSEN2 171/4885APH1B 1760/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | PSEN1 125/4885PSEN2 171/4885APH1B 1760/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | PSEN1 1738/4885PSEN2 2196/4885APH1B 1972/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | PSEN1 1372/4885PSEN2 1853/4885APH1B 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.